What is the dosage and usage of Doxepin for treating depression, anxiety, and insomnia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Doxepin Dosing and Usage

For Insomnia (Primary Indication at Low Dose)

Low-dose doxepin (3-6 mg) is specifically recommended for sleep maintenance insomnia and should be taken at bedtime, with the 6 mg dose showing efficacy for both sleep onset and maintenance. 1, 2

Dosing for Insomnia

  • Sleep maintenance insomnia: 3-6 mg at bedtime 1, 2
  • Sleep onset and maintenance: 6 mg at bedtime 3
  • Maximum dose for insomnia: 6 mg (higher doses increase anticholinergic side effects without additional sleep benefit) 4, 5
  • Can be given on empty stomach to maximize effectiveness 2

Key Advantages for Insomnia

  • Works through selective H1 histamine receptor antagonism at low doses 4, 5
  • Improves wake time after sleep onset, total sleep time, and sleep efficiency significantly better than placebo 3
  • Effects evident after single dose and maintained for up to 12 weeks without tolerance 3
  • No evidence of rebound insomnia, physical dependence, or withdrawal symptoms 3
  • Minimal effects on sleep architecture 5

Position in Treatment Algorithm

  • Second-line pharmacologic option for sleep maintenance insomnia, after cognitive behavioral therapy for insomnia (CBT-I) 2, 6
  • Preferred over trazodone, which has weak evidence and significant adverse effects 2
  • Alternative to benzodiazepine receptor agonists (zolpidem, eszopiclone) when those are contraindicated or have failed 1, 2

For Depression and Anxiety (Higher Dose)

For depression and anxiety disorders, doxepin requires antidepressant doses of 75-300 mg daily, divided or given once at bedtime, with most patients responding to 75-150 mg daily. 7

Dosing for Depression/Anxiety

  • Starting dose: 75 mg daily (can start lower at 25-50 mg in mild cases or elderly) 7
  • Optimal range: 75-150 mg daily 7
  • Severe illness: May increase gradually to 300 mg daily if needed 7
  • Maximum dose: 300 mg daily (rarely provides additional benefit beyond this) 7
  • Can be given as divided doses or once daily at bedtime (maximum 150 mg for once-daily dosing) 7

Approved Indications at Antidepressant Doses

  • Psychoneurotic patients with depression and/or anxiety 7
  • Depression and/or anxiety associated with alcoholism (not taken concomitantly with alcohol) 7
  • Depression and/or anxiety associated with organic disease 7
  • Psychotic depressive disorders with associated anxiety, including involutional depression and manic-depressive disorders 7

Target Symptoms

  • Anxiety, tension, depression, somatic symptoms, sleep disturbances, guilt, lack of energy, fear, apprehension, and worry 7
  • Anti-anxiety effect appears before antidepressant effect 7
  • Optimal antidepressant effect may not be evident for 2-3 weeks 7

Special Populations and Precautions

Elderly Patients

  • Start with low doses (10-25 mg for depression; 3 mg for insomnia) and observe closely 1, 7
  • Elderly are more prone to confusion, oversedation, and anticholinergic effects 7
  • Consider dose reduction due to decreased renal function 7

Contraindications

  • Hypersensitivity to doxepin or other dibenzoxepines 7
  • Glaucoma or tendency to urinary retention (particularly important in older patients) 7
  • Not approved for pediatric use under 12 years 7

Important Warnings

  • Black box warning: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder 7
  • All patients starting antidepressant therapy require close monitoring for clinical worsening, suicidality, or unusual behavior changes 7
  • Avoid in pregnancy and nursing 2
  • Use caution in patients with compromised respiratory function, hepatic or heart failure 2

Drug Interactions

  • At doses up to 150 mg daily, does not block antihypertensive effect of guanethidine 7
  • At doses above 150 mg daily, may block antihypertensive effect 7
  • Caution with concurrent sedating medications due to additive effects 2

Critical Clinical Pitfalls

Common Dosing Errors

  • Do not use low-dose doxepin (3-6 mg) for depression: These doses are inadequate for treating major depressive disorder and only work for insomnia 2
  • Do not use antidepressant doses (75-300 mg) primarily for insomnia: Higher doses cause significant anticholinergic side effects without additional sleep benefit 4

When Low-Dose Doxepin May NOT Work

  • Primary insomnia with comorbid major depressive disorder: Low-dose doxepin (< 25 mg) does not improve sleep onset or maintenance in patients with active MDD 8
  • In this scenario, treat the depression with full antidepressant doses or combine low-dose doxepin with a full-dose antidepressant 1, 2

Comorbid Conditions Requiring Special Consideration

  • Bipolar disorder: Low-dose doxepin (3-6 mg) is preferred over other sedating antidepressants as it has minimal risk of triggering mania at this dose 6
  • Anxiety with insomnia: Both citalopram (20 mg) and low-dose doxepin (12.5 mg) improve sleep and anxiety, though doxepin shows superior improvement in sleep latency 9

Side Effects by Dose

  • Low-dose (3-6 mg): Minimal side effects, mainly sedation/sleepiness and headache at placebo levels 5, 3
  • Antidepressant doses (75-300 mg): Anticholinergic effects (dry mouth, blurred vision, constipation, urinary retention), drowsiness, confusion, cardiovascular effects (hypotension, tachycardia) 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Trazodone for Insomnia Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Low-dose doxepin for the treatment of insomnia: emerging data.

Expert opinion on pharmacotherapy, 2009

Guideline

Best Medication Options for Insomnia in a Patient with Potential Bipolar Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.